{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:07:32Z","timestamp":1774868852475,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40264-022-01244-6","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T06:02:37Z","timestamp":1667282557000},"page":"1517-1527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Topiramate Utilization After Phentermine\/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-9938","authenticated-orcid":false,"given":"Amir","family":"Sarayani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-6364","authenticated-orcid":false,"given":"Christian","family":"Hampp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William Troy","family":"Donahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almut G.","family":"Winterstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"1244_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ecl.2016.04.004","volume":"45","author":"TK Kyle","year":"2016","unstructured":"Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45:511\u201320.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1244_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12916-016-0735-y","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016;14:191. https:\/\/doi.org\/10.1186\/s12916-016-0735-y.","journal-title":"BMC Med"},{"key":"1244_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S2213-8587(17)30236-X","volume":"6","author":"DH Bessesen","year":"2018","unstructured":"Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6:237\u201348.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1244_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","volume":"399","author":"Q Shi","year":"2022","unstructured":"Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399:259\u201369.","journal-title":"Lancet"},{"key":"1244_CR5","unstructured":"Therapeutic Repurposing-National Center for Advancing Translational Sciences (NCATS) [cited 2022 May 10]. Available at: https:\/\/sites.google.com\/ncats.nih.gov\/therapeutic-repurposing\/home."},{"key":"1244_CR6","unstructured":"CURE Drug Repurposing Collaboratory | Critical Path Institute [cited 2022 May 10]. Available at: https:\/\/c-path.org\/programs\/cdrc\/."},{"key":"1244_CR7","doi-asserted-by":"publisher","first-page":"e5524","DOI":"10.1126\/scitranslmed.abd5524","volume":"13","author":"CG Begley","year":"2021","unstructured":"Begley CG, Ashton M, Baell J, Bettess M, Brown MP, Carter B, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med. 2021;13:e5524.","journal-title":"Sci Transl Med."},{"key":"1244_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"1244_CR9","unstructured":"FDA Briefing Information for the February 22, 2012 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. 2012 [cited 2021 Jan 17]. Available at: https:\/\/wayback.archive-it.org\/7993\/20170404152021\/https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/ucm292314.htm."},{"key":"1244_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2146\/ajhp140034","volume":"72","author":"FE Khorassani","year":"2015","unstructured":"Khorassani FE, Misher A, Garris S. Past and present of antiobesity agents: focus on monoamine modulators. Am J Health Syst Pharm. 2015;72:697\u2013706.","journal-title":"Am J Health Syst Pharm"},{"key":"1244_CR11","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018. NCHS Data Brief. United States; 2020. p. 1\u20138."},{"key":"1244_CR12","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/phar.1342","volume":"33","author":"C Hampp","year":"2013","unstructured":"Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299\u2013307.","journal-title":"Pharmacotherapy"},{"key":"1244_CR13","unstructured":"US FDA. Qsymia Prescribing Information (version 2012). 2012 [cited 2021 Jan 17]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022580s000lbl.pdf."},{"key":"1244_CR14","unstructured":"US FDA. Qsymia Approval Letter. 2012 [cited 2021 Jan 17]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2012\/022580Origs000ltr.pdf."},{"key":"1244_CR15","unstructured":"US FDA. Qsymia-Risk Evaluation and Mitigation Strategy (REMS). 2017 [cited 2021 Jan 17]. Available AT: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/rems\/Qysmia_2017-07-03_REMS_full.pdf."},{"key":"1244_CR16","unstructured":"US FDA. Topiramate (Topamax) Prescribing Information (October 2012). 2012 [cited 2021 Dec 5]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020505s050lbl.pdf."},{"key":"1244_CR17","unstructured":"US FDA. REMS Assessment: Planning and Reporting Guidance for Industry. Silver Spring: US FDA; 2019. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rems-assessment-planning-and-reporting."},{"key":"1244_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/cpt.2314","volume":"110","author":"NF Khan","year":"2021","unstructured":"Khan NF, Bykov K, Glynn RJ, Barnett ML, Gagne JJ. Coprescription of opioids with other medications and risk of opioid overdose. Clin Pharmacol Ther. 2021;110:1011\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1244_CR19","unstructured":"Center for Medicare and Medicaid Service: Chronic Conditions Data Warehouse. CCW Condition Algorithms. 2019. Available at: https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories."},{"key":"1244_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmjqs-2019-010098","volume":"29","author":"A Sarayani","year":"2020","unstructured":"Sarayani A, Albogami Y, Elkhider M, Hincapie-Castillo JM, Brumback BA, Winterstein AG. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate. BMJ Qual Saf. 2020;29:636\u201344.","journal-title":"BMJ Qual Saf"},{"key":"1244_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/pds.3894","volume":"25","author":"C-Y Chen","year":"2016","unstructured":"Chen C-Y, Bussing R, Hartzema AG, Shuster JJ, Segal R, Winterstein AG. Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides. Pharmacoepidemiol Drug Saf. 2016;25:678\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1244_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11894-014-0415-z","volume":"16","author":"RT Hurt","year":"2014","unstructured":"Hurt RT, Edakkanambeth Varayil J, Mundi MS, Martindale RG, Ebbert JO. Designation of obesity as a disease: lessons learned from alcohol and tobacco. Curr Gastroenterol Rep. 2014;16:415.","journal-title":"Curr Gastroenterol Rep"},{"key":"1244_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/pds.5371","volume":"31","author":"Y Albogami","year":"2022","unstructured":"Albogami Y, Wei Y-JJ, Winterstein AG. Generalizability and accuracy of IBM MarketScan health risk assessment instrument data for augmentation of commercial claims data. Pharmacoepidemiol Drug Saf. 2022;31:100\u20134.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1244_CR24","unstructured":"Centers for Disease Control and Prevention. Adult obesity prevalence maps\u2014May 2022 Update [cited 2022 Feb 9]. Available at: https:\/\/www.cdc.gov\/obesity\/data\/prevalence-maps.html#overall."},{"key":"1244_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.588016","volume":"12","author":"C Sari","year":"2021","unstructured":"Sari C, Seip RL, Umashanker D. Case report: off label utilization of topiramate and metformin in patients with BMI \u226550 kg\/m2 prior to bariatric surgery. Front Endocrinol. 2021;12:588016.","journal-title":"Front Endocrinol"},{"key":"1244_CR26","unstructured":"Sarayani A, Albogami Y, Winterstein AG. Effectiveness of risk evaluation and mitigation strategies to prevent maternal exposure to a Topiramate weight loss product. Pharmacoepidemiol Drug Saf. 2019;28:245\u20136."},{"key":"1244_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40264-021-01053-3","volume":"44","author":"Y Albogami","year":"2021","unstructured":"Albogami Y, Sarayani A, Hincapie-Castillo JM, Winterstein AG. Real-world fetal exposure to acne treatments in the United States: a retrospective analysis from 2006 to 2015. Drug Saf. 2021;44:447\u201354.","journal-title":"Drug Saf"},{"key":"1244_CR28","doi-asserted-by":"publisher","first-page":"263.e1","DOI":"10.1016\/j.ajog.2022.01.004","volume":"227","author":"A Sarayani","year":"2022","unstructured":"Sarayani A, Albogami Y, Thai TN, Smolinski NE, Patel P, Wang Y, et al. Prenatal exposure to teratogenic medications in the era of risk evaluation and mitigation strategies. Am J Obstet Gynecol. 2022;227:263.e1-263.e38.","journal-title":"Am J Obstet Gynecol"},{"key":"1244_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ijo.2017.287","volume":"42","author":"G Gomez","year":"2018","unstructured":"Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes. 2018;42:495\u2013500.","journal-title":"Int J Obes"},{"key":"1244_CR30","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/pds.4617","volume":"27","author":"EM Ammann","year":"2018","unstructured":"Ammann EM, Kalsekar I, Yoo A, Johnston SS. Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data. Pharmacoepidemiol Drug Saf. 2018;27:1092\u2013100.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1244_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/osp4.450","volume":"6","author":"S Samadoulougou","year":"2020","unstructured":"Samadoulougou S, Idzerda L, Dault R, Lebel A, Cloutier A, Vanasse A. Validated methods for identifying individuals with obesity in health care administrative databases: a systematic review. Obes Sci Pract. 2020;6:677\u201393.","journal-title":"Obes Sci Pract"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01244-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01244-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01244-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:13:52Z","timestamp":1669414432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01244-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01244-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"26 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Almut Winterstein has received funding from the FDA, National Institutes of Health (NIH), Patient-Centered Outcomes Research Institute (PCORI), Agency for Healthcare Research and Quality (AHRQ), the Bill and Melinda Gates Foundation, Merck & Co. and the state of Florida, and has also received consulting honoraria from Arbor Pharmaceuticals and Genentech. She is a special government employee of the FDA and served as the Chair of the Drug Safety and Risk Management (DSaRM) Advisory Committee from 2012 to 2018. None of this funding is related to the current project or poses a conflict of interest. Christian Hampp is employed by Regeneron Pharmaceuticals, Inc., and owns company stock. Regeneron did not provide study funding, does not hold a marketing license for any of the study drugs, and had no role in manuscript development and the decision to publish. Amir Sarayani, Joshua D. Brown, and William Troy Donahoo report no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was received to conduct this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ethical approval was not needed due to the use of de-identified data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Available via an appropriate data use agreement with the vendor.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Available upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AS: Study conception, study design, data analysis, interpretation of results, initial manuscript draft. CH, WD, JB: Study design, interpretation of results, manuscript revision. AW: Study design, data acquisition, interpretation of results, manuscript revision. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}